Dose-related depressive symptoms and suicidal ideation during cabergoline therapy in an adolescent with macroprolactinoma.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Cabergoline is the preferred medical treatment for prolactinomas in children and adolescents because of its efficacy in reducing prolactin concentrations and tumor size. Although dopamine agonists are generally well tolerated, neuropsychiatric adverse effects have been reported, with depressive symptoms and suicidal ideation less frequently described. We report a 15-year-old girl with macroprolactinoma who developed low mood, emotional dysregulation, crying spells, reduced appetite, sleep-wake disturbance, loss of interest in previously enjoyable activities, and passive suicidal thoughts after cabergoline was increased to 1 mg twice weekly. She had no previous psychiatric history, major psychosocial stressor, manic symptoms, or psychotic features. Psychiatric assessment identified moderate depressive symptoms, with a Patient Health Questionnaire-9 score of 11. Cabergoline was reduced to 0.75 mg twice weekly because of the close temporal relationship between dose escalation and symptom onset. Her psychiatric symptoms almost completely resolved within a few days, while prolactin remained controlled. The temporal association, apparent dose relationship, and rapid improvement following dose reduction suggest a cabergoline-associated neuropsychiatric adverse reaction. Clinicians should monitor mood and suicidal ideation during dopamine agonist therapy, particularly after dose escalation and in adolescents.